AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: AstraZeneca is conducting a clinical study titled ‘A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)’. The study aims to evaluate the safety, tolerability, and efficacy of AZD0120 in adults with refractory SLE, a challenging autoimmune condition.
Intervention/Treatment: The study tests AZD0120, a dual CAR T cell therapy targeting CD19 and BCMA, designed to treat refractory SLE. Participants receive a single infusion of AZD0120 following lymphodepleting chemotherapy with Cyclophosphamide and Fludarabine.
Study Design: This is an interventional, single-arm, open-label, multi-center study with a sequential intervention model. It is divided into two phases: Phase 1b focuses on safety and tolerability, while Phase 2 assesses the efficacy of the selected dose. There is no masking involved, and the primary purpose is treatment.
Study Timeline: The study began on April 21, 2025, with the latest update submitted on August 13, 2025. These dates are crucial as they mark the study’s progress and provide a timeline for potential results and subsequent phases.
Market Implications: The successful development of AZD0120 could significantly enhance AstraZeneca’s market position in the autoimmune treatment sector, potentially boosting investor confidence and stock performance. This study positions AstraZeneca against competitors in the innovative CAR T therapy space, which could influence industry dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.